AUTL
Autolus Therapeutics Plc
NASDAQ · Healthcare · Biotechnology · GB
$1.94
+1.04%Sep 9, 2026, 11:00 UTC
The U.S. Food and Drug Administration granted regenerative medicine advanced therapy (RMAT) designation to Autolus Therapeutics' obecabtagene autoleucel (obe-cel) for the treatment of systemic lupus erythematosus and lupus nephritis.
Source:Aug 3, 2026, 11:13 UTC
Autolus Therapeutics reported preliminary second quarter 2026 net product revenue of approximately $45 million for AUCATZYL and a year-to-date gross margin of approximately 35%.
Aug 3, 2026, 11:13 UTC
Autolus Therapeutics announced a five-year, interest-only credit facility of up to $250 million with Perceptive Advisors, with $75 million funded at close.
Source:Jun 12, 2026, 08:00 UTC
Autolus Therapeutics received the 2026 Prix Galien UK Award for Best Biotechnology Product from the Galien Foundation.
Source: